GH Secretagogues
MGF (Mechano Growth Factor)
← Back to Library
Limited / unverified Limited / unverified Limited / unverified GH Axis Repair
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous, Intramuscular
Typical vial sizes: 2, 5 mg
Dosing window: Post-Workout
Receptor / target: IGF-1 Splice Variant
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Post-Workout | 100mcg to 200mcg | Administered bilaterally directly into the trained muscle group immediately post-workout. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 100 mcg 1x Daily | |
| Week 2 | 150 mcg 1x Daily | |
| Week 3 | 200 mcg 1x Daily | |
| Week 4 | 250 mcg 1x Daily | |
| Weeks 5-8 | 300 mcg 1x Daily |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (IGF-1 Splice Variant); route Subcutaneous/Intramuscular; timing Post-Workout. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active cancer: IGF-1 splice variant activity may accelerate tumor proliferation via satellite cell and IGF-1 receptor pathways. Limited / unverified
- History of hormone-sensitive malignancies: breast, prostate, colorectal; IGF-1 receptor activation promotes growth in these tumor types. Limited / unverified
- Diabetic ketoacidosis. Limited / unverified
- Hypoglycemia or hypoglycemia unawareness: MGF shares IGF-1 receptor activity and can lower blood glucose. Limited / unverified
- Active inflammatory myopathy or muscle disease: satellite cell activation in inflamed muscle may worsen the condition. Limited / unverified
- Pregnancy: safety not established. Limited / unverified
- Breastfeeding: safety not established. Limited / unverified
- Known hypersensitivity to MGF or excipients. Limited / unverified
- Intramuscular injection contraindicated in subjects on anticoagulant therapy: IM injection carries bleeding risk. Limited / unverified
- Pediatric use: safety and efficacy not established. Limited / unverified
Side effects (limited evidence)
- Hypoglycemia: the primary and most clinically significant risk; MGF activates IGF-1 receptors which have insulin-like glucose-lowering activity; risk is elevated with fasted administration, high doses, or stacking with IGF-1 LR3; always administer with carbohydrates and protein available. Limited / unverified
- Localized injection site swelling: intramuscular injection causes localized inflammatory response; bilateral swelling of injected muscle groups is expected and typically resolves within 24-48 hours. Limited / unverified
- Pain and soreness at IM injection sites. Limited / unverified
- Excessive localized muscle swelling if dosing is imprecise: injecting too high a dose into a single small muscle (e.g., bicep) can cause disproportionate swelling. Limited / unverified
- Fatigue: transient; associated with satellite cell mobilization and the recovery process. Limited / unverified
- Headache: rare; associated with acute IGF-1 receptor activity. Limited / unverified
- Nausea: rare; dose-dependent. Limited / unverified
- Risk of inefficacy with improper administration timing: the 5-7 minute half-life means delayed post-workout injection substantially reduces efficacy; timing precision is required. Limited / unverified
- No significant systemic side effects at standard localized doses: the short half-life limits systemic exposure when injected IM; most adverse effects are localized. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.